Stock Mover of The Day: Could Acorda Therapeutics Inc Lose Strenght? The Stock Increases A Lot Today

Stock Mover of The Day: Could Acorda Therapeutics Inc Lose Strenght? The Stock Increases A Lot Today

The stock of Acorda Therapeutics Inc (NASDAQ:ACOR) is a huge mover today! About 321,182 shares traded hands. Acorda Therapeutics Inc (NASDAQ:ACOR) has declined 36.85% since April 4, 2016 and is downtrending. It has underperformed by 37.94% the S&P500.
The move comes after 7 months positive chart setup for the $777.73M company. It was reported on Nov, 4 by Barchart.com. We have $24.31 PT which if reached, will make NASDAQ:ACOR worth $334.42M more.

Acorda Therapeutics Inc (NASDAQ:ACOR) Ratings Coverage

Out of 2 analysts covering Acorda Therapeutics (NASDAQ:ACOR), 1 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 50% are positive. Acorda Therapeutics has been the topic of 8 analyst reports since August 25, 2015 according to StockzIntelligence Inc. The rating was initiated by Aegis Capital on Tuesday, September 1 with “Buy”. The company was maintained on Tuesday, August 25 by Cowen & Co. Raymond James initiated Acorda Therapeutics Inc (NASDAQ:ACOR) on Tuesday, September 1 with “Market Perform” rating. The company was maintained on Wednesday, January 6 by Aegis Capital. The firm has “Buy” rating given on Tuesday, August 25 by TheStreet. The stock of Acorda Therapeutics Inc (NASDAQ:ACOR) earned “Neutral” rating by Goldman Sachs on Wednesday, March 30. The company was maintained on Tuesday, August 25 by Stifel Nicolaus. The stock has “Neutral” rating given by JP Morgan on Tuesday, August 25.

According to Zacks Investment Research, “Acorda Therapeutics is commercial-stage biopharmaceutical company dedicated to the identification, development and commercialization of novel therapies that improve neurological function in people with multiple sclerosis, spinal cord injury and other disorders of the central nervous system. Acorda currently markets Zanaflex Capsules for the management of spasticity. The Company’s lead product candidate, Fampridine-SR, for the improvement of walking ability in persons with multiple sclerosis. It develops therapies that restore neurological function to people with spinal cord injury, multiple sclerosis and related conditions of the nervous system.”

Insitutional Activity: The institutional sentiment decreased to 1.13 in 2016 Q2. Its down 0.28, from 1.41 in 2016Q1. The ratio is negative, as 32 funds sold all Acorda Therapeutics Inc shares owned while 45 reduced positions. 14 funds bought stakes while 73 increased positions. They now own 43.11 million shares or 7.66% less from 46.68 million shares in 2016Q1.
The Arizona-based Tci Wealth Advisors has invested 0% in Acorda Therapeutics Inc (NASDAQ:ACOR). D E Shaw holds 0.03% or 547,815 shares in its portfolio. Amer Int Gru holds 0% or 32,517 shares in its portfolio. The Ohio-based Meeder Asset Management Incorporated has invested 0.01% in Acorda Therapeutics Inc (NASDAQ:ACOR). Geode Cap Mngmt Lc accumulated 362,496 shares or 0.01% of the stock. Employees Retirement Association Of Colorado accumulated 319,099 shares or 0.07% of the stock. The Massachusetts-based Wellington Management Group Incorporated Ltd Liability Partnership has invested 0.01% in Acorda Therapeutics Inc (NASDAQ:ACOR). Checchi Advisers Lc holds 0% or 16 shares in its portfolio. Alps Inc holds 64,714 shares or 0.01% of its portfolio. Swiss Natl Bank holds 78,600 shares or 0% of its portfolio. State Of New Jersey Common Pension Fund D has invested 0.01% of its portfolio in Acorda Therapeutics Inc (NASDAQ:ACOR). Pnc Financial Services Grp Incorporated holds 0% of its portfolio in Acorda Therapeutics Inc (NASDAQ:ACOR) for 7,712 shares. Blackrock Institutional Tru Na has invested 0.01% of its portfolio in Acorda Therapeutics Inc (NASDAQ:ACOR). Brown Brothers Harriman has invested 0% of its portfolio in Acorda Therapeutics Inc (NASDAQ:ACOR). Sector Pension Inv Board holds 0.01% of its portfolio in Acorda Therapeutics Inc (NASDAQ:ACOR) for 32,205 shares.

Insider Transactions: Since May 13, 2016, the stock had 0 insider buys, and 6 selling transactions for $295,778 net activity. RAUSCHER STEVEN M also sold $30,224 worth of Acorda Therapeutics Inc (NASDAQ:ACOR) shares. Wasman Jane had sold 500 shares worth $13,660. LAWRENCE DAVID also sold $5,205 worth of Acorda Therapeutics Inc (NASDAQ:ACOR) shares. $41,877 worth of Acorda Therapeutics Inc (NASDAQ:ACOR) was sold by Batycky Richard P.. Shares for $126,885 were sold by Hindman Andrew A. on Friday, May 13.

Another recent and important Acorda Therapeutics Inc (NASDAQ:ACOR) news was published by Nasdaq.com which published an article titled: “Oversold Conditions For Acorda Therapeutics” on October 27, 2016.

ACOR Company Profile

Acorda Therapeutics, Inc., incorporated on March 17, 1995, is a biopharmaceutical company. The Firm is engaged in the identification, development and commercialization of therapies that restore function and recovers the lives of people with neurological disorders. The Company’s commercial products include Ampyra, Fampyra, Zanaflex Capsules and a generic version of the capsules, Zanaflex tablets and Qutenza. The Company’s research and development programs include CVT-301, Dalfampridine, Plumiaz, Neuregulin Program, Remyelinating Antibodies Program, CVT-427 and Chondroitinase Program. The Company’s Ampyra (dalfampridine) Extended Release Tablets, 10 milligrams, is used as a treatment to improve walking in patients with multiple sclerosis (MS). It also markets Zanaflex Capsules and tablets, which are short-acting drugs for the management of spasticity, and Qutenza, a dermal patch for the management of neuropathic pain associated with post-herpetic neuralgia, also known as post-shingles pain. The Company’s pipeline of neurological therapies addresses a range of disorders, including MS, Parkinson’s disease, chronic post-stroke walking deficits (PSWD), epilepsy and migraine.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Tags: , ,

Related posts

Leave a Comment